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Abstract: 
Background: Respiratory Syncytial Virus (RSV) is the leading cause of severe lower 
respiratory tract infection in infants and children worldwide. Early diagnosis of RSV infection 
is associated with shorter periods of hospitalisation and decreased mortality. Current point of 
care (PoC) tests for RSV is less sensitive than molecular methods. Reverse transcription 
loop-mediated isothermal amplification (RT-LAMP), is a novel method of nucleic acid 
detection which allows for rapid, robust amplification, and visual detection of infectious 
agents. 
Aim: The objective of this study was to develop a novel, rapid, and sensitive multiplex RSV 
RT-LAMP assay for PoC diagnosis of RSV A and B.  
Methods: Preparation of a quantitative RSV standard for assay optimisation was done using 
a rapid hypotonic burst recovery method of infective virus during sub-passaging, and a shell 
vial fluorescent focus assay for titration of culture-derived viral stock. We designed a single 
set of eight primers targeting the large polymerase gene of both RSV A and B, and 
developed a novel single-step multiplex RSV RT-LAMP assay, using an in-house reaction 
mix and the Rotor-Gene Q real-time thermocycler (Qiagen, Hilden, Germany). The metal ion 
indicator hydroxy naphtol blue (HNB) was added to the multiplex RSV RT-LAMP assay for 
visual detection of RSV. 
Results: The final optimised multiplex RSV RT-LAMP assay had an analytical detection 
sensitivity of <10 focus forming units (FFU) per reaction for both RSV A and B, with a mean 
time to positivity of 21.85 minutes (95% CI 19.2-24.5 minutes), compared to 90-120 minutes 
for conventional PCR. Evaluated against the Seeplex RV15 multiplex PCR (Seegene, Seoul, 
Korea) by testing 44 (22 RSV A/22 RSV B) nasopharyngeal specimens, the multiplex RSV 
RT-LAMP assay had a sensitivity of 100%, and a specificity of 100% when screened against 
nine common respiratory viruses. Visual detection of RSV using HNB as colorimetric reagent 
was equivalent to the analytical sensitivity (10 FFU/reaction) and specificity (100%) of the 
multiplex RSV RT-LAMP assay.  
Conclusion: Compared with conventional PCR, our novel single-step multiplex RSV RT-
LAMP assay had excellent sensitivity, specificity, and when combined with HNB dye could 
provide accurate visual diagnosis within 1 hour. We envisage that this multiplex RSV RT-
LAMP assay will be used for rapid and sensitive RSV detection at the PoC. 
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Opsomming:  
Agtergrond: Respiratoriese Syncytial Virus (RSV) is die hoof oorsaak van erge laer 
lugweginfeksie in babas en kinders wêreldwyd. Vroeë diagnose van RSV infeksie word 
geassosieer met korter periodes van hospitalisasie en verlaagde mortaliteit. Huidige punt van 
sorg (PoC) toetse vir RSV is minder sensitief as molekulêre metodes. Omgekeerde 
transkripsie lus-gemedieerde isotermiese amplifisering (RT-LAMP), is 'n nuwe metode van 
nukleïensuur opsporing wat voorsiening maak vir vinnige, doeltreffende amplifisering, en 
visuele bevestiging van aansteeklike agente. 
Doel: Die doel van hierdie studie was om 'n nuwe, vinnige en sensitiewe multipleks RSV RT-
LAMP toets te ontwikkel wat PoC diagnose van RSV A en B in staat stel.  
Metodes: Voorbereiding van 'n kwantitatiewe RSV standaard vir toets optimisering is gedoen 
met behulp van 'n hipotoniese sel-lise metode van infektiewe virus tydens sub-kultuur, en 'n 
“shell-vial” kultuur en fluorosensie fokus toets vir titrasie van kultuur-geproduseerde virus 
voorraad. Ons het 'n enkele stel van agt inleiers ontwerp wat gebaseer is op die groot 
polimerase geen van beide RSV A en B, en 'n nuwe enkel-stap multipleks RSV RT-LAMP 
toets ontwikkel, met gebruik van 'n in-huis reaksie mengsel en die Rotor-Gene Q “real-time” 
thermocycler (Qiagen, Hilden, Duitsland). Die metaalioon aanwyser hidroksi naphtol blou 
(HNB) is bygevoeg in die multipleks RSV RT-LAMP toets vir visuele bevestiging van RSV. 
Resultate: Die finale geoptimiseerde multipleks RSV RT-LAMP toets het 'n analitiese 
sensitiwiteit van <10 fokus vormende eenhede (FFU) per reaksie vir beide RSV A en B 
gehad, met 'n gemiddelde tyd tot positiwiteit van 21.85 minute (95% CI 19.2-24.5 minute) , in 
vergelyking met 90-120 minute vir konvensionele PCR. Geëvalueer teen die Seeplex RV15 
multipleks PCR (Seegene, Seoul, Korea) deur 44 (22 RSV A/22 RSV B) nasofaringeale 
monsters te toets, het die multipleks RSV RT-LAMP toets 'n sensitiwiteit van 100% getoon, 
en 'n spesifisiteit van 100% wanneer getoets teen nege algemene respiratoriese virusse. 
Visuele bevestiging van RSV met gebruik van HNB as kolorimetriese reagens was 
gelykstaande aan die analitiese sensitiwiteit (10 FFU/reaksie) en spesifisiteit (100%) van die 
multipleks RSV RT-LAMP toets. 
Gevolgtrekking: In vergelyking met konvensionele PCR, het ons nuwe enkel-stap multipleks 
RSV RT-LAMP toets uitstekende sensitiwiteit, spesifisiteit, en wanneer dit gekombineer word 
met HNB kleurstof kon dit akkurate visuele diagnose voorsien binne 1 uur. Ons verwag dat 
hierdie multipleks RSV RT-LAMP toets gebruik sal word vir vinnige en sensitiewe RSV 
bevestiging by die PoC.  
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Chapter 1: Introduction 
1.1 Background  
Globally, the burden of disease from respiratory infection exceed that of all other cause of 
illness.1 Acute lower respiratory tract infection (ALRTI) contributes substantially to the public 
health burden of respiratory infections, and unlike mild self-limiting upper respiratory 
infections such as rhinitis or pharyngitis, often requires hospitalisation. ALRTI affects all age 
groups, but is more prevalent during early childhood compared to adulthood,2 and is the 
leading cause of paediatric morbidity and mortality;3, 4 it poses a significant challenge to 
accomplishment of Millennium Development Goal 4 –to reduce child mortality by two thirds 
by 2015.5  
An important respiratory viral pathogen is Respiratory syncytial virus (RSV); it is the primary 
aetiological agent associated with severe ALRTI in infancy and young children worldwide,6 
and accounts for the major proportion of ALRTI-associated hospitalisations within the first 
year of life.7  
1.2 Virus properties 
RSV is part of the Paramyxoviridae family and a member of the genus Pneumovirus; two 
distinct genogroups have been identified, RSV group A and B, based on their respective 
antigenicity.8 The RSV genome is non-segmented, with a single strand of negative-sense 
RNA molecule, approximately 15.2 kb in length, forming an enveloped nucleocapsid and has 
10 genes that encode 11 major viral proteins.9 Three of these polypeptides are trans-
membrane envelope glycoproteins (G, F and SH); the heavily glycosylated G protein is 
responsible for viral attachment to the cell, whilst the F protein mediates cell-to-cell fusion; 
the G and F proteins have been identified as the primary components to exhibit protective 
antigenic properties, and are thus of clinical significance.10  
The structural proteins within the nuclear capsule include: the large RNA polymerase (L), the 
nucleoprotein (N), and the phosphoprotein (P); collectively these proteins comprise the RSV 
replicase.11 A structural, non-glycosylated matrix protein (M), is thought to play an important 
role in viral budding through the association between the nucleocapsid and viral envelope.12 
Lastly, two non-structural proteins (NS1 and NS2), accumulating only in small amounts 
during infection, appear to possess an ancillary function of down regulating viral RNA 
synthesis by inhibition of host type 1 interferon induction.13  
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1.3 Pathogenesis 
The incubation period of RSV is approximately 3-5 days, and viral transmission occurs 
mostly through the nose by inhalation of large aerosolised nuclei, or through hand-to-eye 
contact with infectious secretions.14 Early onset of illness is characterised by upper 
respiratory tract infection, with viral replication in the nasopharynx, followed by migration to 
the lower airways, showing a particular tropism for the bronchiolar epithelium.15 Unlike many 
viruses, infectious RSV virions spread from cell to cell, independent of the extracellular 
milieu, by inducing cell fusion and forming syncytia – the cytopathic hallmark of infection.16 
This enables the virus to escape the humoral (antibody) immune response, and may explain 
why RSV is the first respiratory pathogen to affect infants, despite being born with high titres 
of maternal transplacentally-acquired antibodies.17 
Infection is restricted to polarised, superficial ciliated cells,18 entering via the apical 
membrane,19 and initially leads to peribronchiolar inflammation with lymphocytes, which 
progresses to necrosis and desquamation of the bronchiolar epithelium.20 As infection 
develops, the resultant necrotic cell debris mixes with increased airway mucosal exudate, 
forming thick intraluminal plugs, causing the typical pathology of airway blockade and 
hyperinflation associated with ALRTI.21    
1.4 Epidemiology 
The nidus of RSV infection predominates in humans who are the only natural host, although 
RSV infection and severe disease in non-human primates has been observed on occasion.22 
Infection by RSV is highly contagious and previous exposure to RSV does not confer 
immunity to multiple infections recurring throughout life.23 Infection has seasonal 
epidemiology, occurring typically during winter in temperate climates and in the rainy season 
throughout tropical regions, resulting in an estimated 64 million cases of severe respiratory 
disease and 160 000 deaths annually worldwide.24 In addition, shifts in the predominance of 
antigenic subgroups occur in yearly cycles, with even co-circulation of multiple strains within 
subgroups common,25 which further enhances immune evasion by the heterologous strain to 
antecedently induced protection.26    
The majority of children under 1 year are infected by RSV and almost all are infected before 
the age of two.27 A recent study reported RSV as the cause of 34 million cases of ALRTI in 
children younger than 5 years globally. The bulk of these ALRTI cases occur in resource-
limited settings,28 with 99% of the more than 66 000 annual deaths of children under the age 
of 5 being in developing countries.7  
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Whilst the effect of RSV infection in children is well known, there is also growing recognition 
of the importance of RSV-associated ALRTI in the elderly that seem more frequent in 
developed countries and in contrast to the greater paediatric cases in less affluent countries, 
with an annual average of 17 358 deaths of adults older than 65 estimated in the USA 
alone.29 Taken together, this contributes to a large and periodic burden on health care 
infrastructure, with hospitalisation costs per case of RSV estimated at an average of 
US$5 250.30 
1.5 Risk factors 
There are several important risk factors that affect the severity of RSV disease. The 
pathology of RSV infection means infants and young children are inherently predisposed to 
ALRTI due to an immature immune system.31 Furthermore, prematurity goes together with 
small and vulnerable airways, low titres of maternally derived RSV neutralising antibody 
transfer,32 and insufficient cell-mediated immunity, leading to higher ICU admission and 
longer hospitalisation,33 along with a significant increase (15.4%) in the rehospitalisation rate 
of preterm infants who developed chronic pulmonary disease (mostly bronchopulmonary 
dysplasia).34   
High risk populations particularly susceptible to severe ALRTI by RSV are those that 
underwent immunosuppression therapy from solid organ and hematopoietic stem cell 
transplantation,35 or suffer from immunodeficiency as shown by a study in South Africa that 
highlighted increased mortality in children with human immunodeficiency virus (HIV).36 The 
other main epidemiological factors are congenital heart disease,37 and delayed onset of 
breastfeeding.38   
The presence of viral co-infection and its influence on disease severity is controversial with 
conflicting studies,39 whilst a recent study described the importance of RSV subgroup in 
disease severity, reporting increased duration of hospital stay and more frequent fatality in 
patients infected with RSV A.40 Seldom studied environmental and other host related risk 
factors that are associated with variable increase of RSV disease severity and rate of 
hospitilisation, which require further investigation include: maternal smoking and household 
smoke pollution,41 low socioeconomic status,42 crowded living conditions,43 and living at 
altitude.44      
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1.6 Treatment and prevention 
Therapy of RSV disease is limited to post-hospitalisation supportive care and palliative 
measures, usually by oxygen therapy and treatment with the only FDA approved RSV 
antiviral –Ribavirin. Various alternative treatment strategies have been attempted over the 
years, such as the use of racemic epinephrine, aerosolised recombinant human DNase or 
corticosteroids, but clinical testing of these showed no efficacious outcome.45  
To date, the only form of specific RSV prevention is by systemic immunoprophylaxis, 
currently administered exclusively for high-risk groups with Palivizumab (Synagis®; 
MedImmune, Gaithersburg, USA), which is a neutralising monoclonal antibody (mAb) 
specific to the F protein of RSV.46 Motavizumab is a 2nd generation mAb Palivizumab-
derivative that proved more potent and could be administered at lower doses compared to 
Palivizumab, however the adverse hypersensitivity observed in patients during trials 
ultimately led to non-approval of the drug.47  
A number of promising candidate vaccines for active immunisation, using the approach of 
reverse genetics technology to target gene deletion of a viral genome, are under 
development and trial,48, 49 but clinical efficacy has not yet been established. The central 
challenge for live RSV vaccine development is to attain a safe balance between attenuation 
and immunogenicity –a highly important factor when considering the partly-competent infant 
immune system that lacks appropriate B-cell response and antigen presentation.50  
The high risk of RSV infection in very young infants, before postnatal vaccination courses 
would have an effect, makes the option of passive immunity conferred to an infant through 
maternal vaccination during gestation attractive.51 Although one vaccine candidate has 
entered clinical trial,52 the difficulty of this strategy is the requirement of the vaccine to induce 
the infant immune system to retain high titres of antibodies as maternal antibodies wane in 
the neonate. Thus, a successful vaccine that would provide protection to infants and high risk 
individuals from all age groups remains a priority and a challenge to develop.  
1.7 Diagnosis 
Effective RSV diagnosis allows for correct treatment or management of patients admitted for 
severe ALRTI, is associated with shorter periods of hospitalisation, and is paramount to 
decrease disease morbidity and mortality.53 Furthermore, timely detection of RSV as cause 
of ALRTI in patients lowers the number of auxiliary tests, ensuring institution of appropriate 
treatment which is useful to reduce antibiotic use often unrequired in most cases of viral 
ALRTI,54 and through isolation of infected patients prevent nosocomial infections.55  
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Rapid and sensitive RSV detection is also crucial to drive preventative programs, evaluate 
antiviral vaccine efficacy, and provides a valuable tool for epidemiologic monitoring of RSV 
spread.56 
1.7.1 Conventional methods 
Cell culture isolation of RSV used to be regarded for many years as the gold standard for 
detection of RSV infection. However, the growth of RSV in culture is slow and arduous to 
perform, with time to cytopathic effect (CPE) post-inoculation often only observed after 7 
days.57 In addition, a fair amount of technical expertise is required to ensure correct and 
efficient virus recovery during the chain from sample collection to culture inoculation. An 
advantage of the culture method is that it enables subsequent genetic and antigenic 
molecular investigation when the virus is amplified, which is useful for mutation screening 
and viral transmission analysis.58, 59 
Antigen detection of RSV is done by direct immunofluorescence assays (DFA) that use 
fluorescein-labelled antibody detection in epithelial cells,60 RSV-specific enzyme-linked 
antibody capture through enzyme immunosorbent assays (EIA),61 and chromatographic 
assays.62 DFA has the benefit of direct observation of infected cells by microscopy, whilst 
EIA are easily performed and provide rapid confirmation (approximiately 15 minutes), and 
are thus generaly undertaken in clinical practice for RSV diagnosis. Despite these 
advantages, a high rate of misdiagnosis (10-30%) and poor specificity has been reported 
when antigen detection methods are used alone,63, 64 and EIA lacks adequate sensitivity for 
RSV confirmation in older children and adults who possess lower viral titres.65 
1.7.2 Molecular detection 
Over the last decade gene amplification by nucleic acid tests (NATs) has become the new 
gold standard for the detection of numerous viral agents including RSV, as superior 
sensitivity and specificity has been proved when compared to viral isolation and antigen 
detection methods,66, 67 in addition to improved detection efficacy regardless of the age and 
quantity of viral shedding in the patient tested.68, 69  
The most frequently used NATs for detection of respiratory viruses are based on the reverse 
transcription polymerase chain reaction technique (RT-PCR),70 with several in-house formats 
developed amplifying various RSV gene targets.71, 72 Furthermore, a number of commercially 
available isothermal amplification techniques have been introduced either using strand 
displacement amplification (SDA), or transcription-mediated amplification (TMA).73  
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Other PCR methods allow simultaneous amplification and detection of a virus genome in 
real-time by quantitative real-time PCR (q-PCR). These real-time PCR assays typically 
employ TaqMan fluorescent probes,74 scorpion probes,75 or molecular beacons,76 and result 
in a substantial reduction of turnaround time (TAT) to a few hours. Notwithstanding, the 
undeniable weakness of all these nucleic amplification-based assays, when considering the 
diagnostic end-to-end process holistically, is the necessity of costly equipment and 
specialised infrastructure which limit their diagnostic utility at the point of care (PoC), 
especially in resource-poor settings.  
1.7.3 LAMP detection 
Loop-mediated isothermal amplification (LAMP) is a gene-specific isothermal nucleic acid 
amplification method developed by Notomi et al. (2000). Unlike PCR, which denatures 
double-stranded DNA (dsDNA) with heat, strand separation of dsDNA in LAMP is performed 
by enzymatic activity of a Bst DNA polymerase. The high degree of specificity and excellent 
sensitivity of the LAMP method is attributed to the use of 4 main primers (2 inner and 2 outer 
primers) designed to recognise six distinct regions of the target sequence, with two primers 
consisting of complementary sequence in order to make loop structures that initiate self-
elongation and subsequent continual strand displacement, generating rapid exponential 
amplification that yields significant total DNA synthesis, and can be run at a constant 
temperature without the use of expensive instrumentation.77, 78 Addition of two more primers 
called loop primers further accelerates the reaction speed.79 Lamp typically provides equal or 
improved detection limits than that of PCR but with much faster reaction time (within 1 
hour),80, 81 and amplified products can be assessed not only by fluorescent RT-PCR, but 
through measurement of turbidity,82 or visual observation of a change in reaction colour.83  
1.8 Research statement    
Taken together, the highlighted advantages of LAMP make it particularly applicable and 
versatile for efficient and cost-effective RSV diagnosis at the PoC in a low-resource 
environment. With this in mind, the objective of this study was to develop and optimise a 
sensitive multiplex LAMP assay for rapid detection of both RSV group A and B, which we 
hypothesise, will improve PoC diagnosis of paediatric and adult RSV suspects. 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
7 
Chapter 2: Materials and Methods 
2.1 Clinical specimens and viral isolates 
The study was laboratory based; nasopharyngeal (NP) specimens were used, collected from 
patients with symptomatic ALRTI from June 2011 to July 2013 at (Tygerberg Hospital, Cape 
Town, South Africa), as part of routine laboratory testing by the (NHLS, Tygerberg Hospital). 
All NP specimens were suspended in 5 ml of viral transport media (VTM) containing Eagle‟s 
minimum essential medium (MEM; Lonza, Basel, Switzerland), supplemented with 0.2 ml 
Penicillin-Streptomycin antibiotic cocktail (ABC; Lonza, Basel, Switzerland), and stored at -
80°C for future use at the Division of Medical Virology, Stellenbosch University. Stored 
residual laboratory viral isolates used in the preparation of viral standards, for optimisation 
and validation of the RSV RT-LAMP assay, were de-identified and assigned new isolate 
numbers not related to patient information. This study was approved by the Stellenbosch 
University Health Research Ethics Committee (N11/09/300).  
2.2 Preparation of viral standards  
2.2.1 Growth of cell lines 
In vitro propagation of RSV is done in Human epithelial type 2 (HEp-2) and Maiden Darby 
canine kidney (MDCK) cell lines. Continuous HEp-2 and MDCK cell lines to be used for 
downstream cell culture assays were passaged as follows: (All standard cell culture 
laboratory measures to prevent contamination were adhered to). Cryogenically preserved 
HEp-2 and MDCK cell stocks, acquired from the American Tissue Culture Collection (ATCC; 
Manassas, USA), were resuscitated by rapidly thawing the frozen ampoules at 37°C for 2 
minutes, and whole ampoule contents transferred to sterile 50 ml Falcon® centrifuge tubes 
(Corning, New York, USA).  
HEp-2 and MDCK cell suspensions were each prepared in 5 ml of modified MEM solution 
containing 10% Foetal bovine serum (FBS; Sigma-Aldrich, St. Louis, USA) heat-inactivated 
at 56°C for 30 minutes , 0.2 ml ABC, 5% Dimethyl sulfoxide (DMSO; Corning, New York, 
USA), 1X Phosphate-buffered Saline without Ca++ and Mg++ (PBS; containing 8.5 mM 
sodium phosphate, 1.5 mM potassium phosphate, and 137 mM NaCl, at pH 7.4), and 200 
mM L-glutamine solution in 0.85% NaCl (Lonza, Basel, Switzerland). The cell suspensions 
were centrifuged at 600 x g for 5 minutes to remove cryoprotectant, after discarding of the 
supernatant, the cell pellets were re-suspended in fresh MEM solution and mixed well by 
vortexing for 1 minute.  
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The accurate number of total viable cells was counted using an Improved Neubauer 
haemocytometer, and cell lines were prepared at a standard final concentration of 15 x 104 
cells/ml;84 30 ml of each cell suspension was inoculated into 75 cm2 CELLSTAR® tissue 
culture flasks (TCF; Greiner Bio-One GmbH, Kremsmünster, Austria), and incubated at 37°C 
for 72 hours to prepare cell monolayers. Growth of monolayers was monitored until 70% 
confluency reached, upon which the medium was discarded, and replaced with 30 ml of 
MEM containing 2% FBS for the maintenance of cell monolayers. Once cell monolayers were 
90%-100% confluent, TCF were incubated at 33°C until used. 
To ensure the continuation of the cell lines, sub-culturing of cell lines was done as follows: 
old medium was discarded from TCF, monolayers were washed with 10 ml of 1X PBS (Ca++ 
and Mg++ free), and incubated for 10 minutes at room temperature with 1 ml of pre-warmed 
1X Activated Trypsin-Versene solution (ATV; Sigma-Aldrich, St. Louis, USA) added for cell 
detachment. Following this cell detachment step, any adherent cells not in suspension were 
dislodged from TCF surfaces using a Porvair cell scraper (Porvair, Wrexham, UK); cells were 
then harvested, re-inoculated into new TCF, and incubated as described above.  
2.2.2 Shell vial culture 
The unavailability of ATCC RSV strains at our laboratory during the cell culture phase of the 
study, which serve as reference standards from the offset, necessitated the cultivation of 
RSV from residual viral isolates. As highlighted before, traditional RSV culture is a timely 
process. Centrifugation-enhanced shell vial (SV) culture is a well-established technique in 
diagnostic virology laboratories. Compared to conventional culture, the SV assay provides a 
much-reduced TAT (24-48 hours) for the detection of ALRTI-associated pathogens,85 
correlates well with traditional methods, is specific, and has been shown to be more sensitive 
for RSV detection.86 A key feature in the SV assay is the utilisation of combinatory cell lines 
for virus propagation.87  
We chose the SV assay for the first step of RSV proliferation, to yield a highly infective initial 
stock that would ensure effective subsequent culture in larger TCF with minimum passage 
number, providing optimal final RSV culture stocks used to prepare our viral standards. SV 
assay was done as follows: A mixed cellular suspension of HEp-2 and MDCK cell lines 
(CoHM) was prepared in Roswell Park Memorial Institute medium (RPMI-1640; Lonza, 
Basel, Switzerland), modified exactly as with MEM, from our established HEp-2 and MDCK 
cell lines, with each cell type seeded at 15 x 104 cells/ml, and combined in equal amounts. 
Sterilin™ 7 ml polystyrene SV tubes (Sterilin, Newport, UK), with a clear round coverslip 
(Lasec, Cape Town, South Africa) inserted, were inoculated with 1 ml amounts of mixed cell 
suspension, and incubated at 37°C in upright position for 24 hours.   
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Semi-confluent SV tubes were aspirated of old medium and 200 μl aliquots of viral isolate 
supernatant, containing either RSV A or RSV B, were delivered to each vial through a Millex® 
syringe filter (Merck Millipore, Billerica, USA). The vials were centrifuged at 1600 x g for 45 
minutes and allowed to adsorb at 37°C for 1 hour. After supernatant removal, 1 ml of MEM 
maintenance medium (2% FBS) was added to each vial, and inoculated vials were incubated 
at 33°C on a continuous shaker for 48 hours.  
2.2.3 RSV visualisation 
Positive RSV growth after SV incubation was determined by indirect immunofluorescent 
(IMF) microscopy as follows: The supernatant of each SV (1.2 ml) was aspirated and aliquots 
stored in 2 ml graduated Eppendorf Tubes® (Greiner Bio-One GmbH, Kremsmünster, 
Austria) at 4°C for downstream use; the coverslips were removed with sterile forceps and 
rinsed by dipping into a bijou containing 1X PBS, then placed for 20 minutes in a bijou filled 
with -20°C acetone to fix cell monolayers formed on the coverslips. Once fixed, coverslips 
were mounted, cells up, on glass microscopy slides (Lasec, Cape Town, South Africa) with 
Entellan® medium (Merck Millipore, Billerica, USA).  
The Light Diagnostics™ Respiratory Panel I Viral Screening and Identification kit (Merck 
Millipore, Billerica, USA) was used for IMF staining as follows: Provided RSV mouse mAb 
was applied to the entire coverslip and the slides incubated in a moist 5% CO2 chamber at 
37°C for 30 minutes. Unbound antibody was washed from the slides with 1X PBS containing 
1X TWEEN® 20 (in the kit), and one drop of fluorescein isothiocyanate (FITC) labelled goat 
anti-mouse IgG was applied to each coverslip, with slides incubated for a further 30 minutes 
at 37°C in a CO2 chamber. Following FITC incubation, provided mounting fluid was applied to 
each dry coverslip and slides were covered with a cover glass. Prepared slides, including a 
negative control from the kit, were read with a ProgRes® ultraviolet (UV) microscope 
(Olympus Soft Imaging Solutions GmbH, Münster, Germany) at X200 magnification. Cells 
positive for RSV exhibited the characteristic apple-green fluorescence of FITC, whilst 
uninfected cells stained a dull red.  
2.2.4 TCF culture  
Sufficient stocks of RSV A and B for preparation of viral standards were cultivated in TCF as 
follows: The SV culture aliquots of infectious supernatant, from the viral isolates that 
presented the most growth of each RSV genogroup, stored previously at 4°C, were added to 
15 ml Corning® centrifuge tubes (Corning, New York, USA), mixed well by vortexing for 1 
minute, and 10 ml of the respective viral supernatants were inoculated into 75 cm2 TCF with 
confluent HEp-2 monolayers readied as before. Inoculated TCF were then incubated at 37°C 
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for 1 hour, to allow cellular adhesion, after which 20 ml of MEM maintenance medium was 
added and TCF incubated at 33°C for 7 days.  
Infected cell monolayers post-TCF incubation were scraped and the cell suspensions were 
transferred to 50 ml centrifuge tubes, homogenised by vortexing for 1 minute, after which 5 
ml aliquots of the cell suspension were made in 15 ml centrifuge tubes and stored at 4°C for 
IMF detection. Stock to be used for viral extraction was stored at 4°C, whilst remaining stock 
was preserved at -80°C. Preparation of microscopy slides for IMF detection was done as 
follows: The aliquots designated for IMF were centrifuged at 600 x g for 10 minutes, after 
pouring off the supernatant, pelleted cells were washed in 5 ml of 1X PBS by vortexing for 1 
minute. The centrifugation step was repeated and the cell pellets were re-suspended in 1 ml 
of 1X PBS. Approximately 10 μl aliquots of the respective cell suspensions were put onto 
separate 12-well microscopy slides (Lasec, Cape Town, South Africa), allowed to air dry for 
20 minutes, and slides were then fixed in -20°C acetone for 10 minutes. The IMF staining 
procedure and reading of the slides was carried out as before.  
Despite good RSV propagation in SV culture, growth of RSV in culture flasks, sufficient for 
preparation of viral standards, could not be replicated. To overcome this problem, several 
measures were subsequently implemented to optimise the cell culture process, so as to 
attain the desired levels of RSV infectivity in culture flasks.    
2.2.5 Cell culture optimisation 
Our first approach focused on the optimisation of the SV assay, to increase viral titres of the 
initial SV culture stock for TCF inoculation even further. This involved the addition of a 2nd 
line of SV culture that would follow 1st line cultivation. With such an increase of passage, an 
important consideration during viral sub-passage is the presence of defective interfering 
particles (DIP).88 DIP lack the full complement of genes necessary for a complete infectious 
cycle, consequently they compete with functional virions which inhibits infection, decreasing 
lot to lot titre reliability and assay reproducibility.89  
To minimise the effect of potential DIP on our SV stock titres, a limiting dilution method was 
used as follows: 1st line SV culture and IMF confirmation was done as before, after which 
limiting dilution series (1:1, 1:10, 1:50, 1:100) of harvested infectious 1st line SV supernatant 
was made; the highest dilution (1:100) was then inoculated onto 2nd line SV tubes and 
cultured as before.  
Furthermore, RSV is an extremely heat labile virus, with elevated loss of infectivity above 
37°C within a day.90 Sucrose has been shown to be an effective stabiliser of RSV under all 
conditions;91 therefore, the recovered viral supernatant after 2nd line SV incubation was 
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supplemented with an equal amount of 25% sucrose solution (25% sucrose in Milli-Q purified 
H2O; Sigma-Aldrich) for improved stabilisation, and stored at 4°C for subsequent TCF 
inoculation. 
As noted before, a primary feature of RSV is the cell-associated nature of its replication 
cycle, which plays an important role in cell culture. Improved virus titres during sub-passage 
can be achieved by releasing intracellular infectious virions into the culture medium. The 
conventional technique used for virion recovery from infected cell cultures is by repeated 
freeze-thaw (F-T) cycles of the infectious medium.92 F-T cycles are laborious and reduce viral 
titres; additionally, a large amount of membrane-bound virions may be lost to cellular waste 
ensuing from the technique.93 A recent study employed the use of direct water lysis to induce 
cell-breakage of avian metapneumovirus (AMPV),94 by creating a hypotonic environment 
within the cell medium, leading to an increase of water pressure inside cells and their 
eventual rupture. This method avoids repeated F-T cycles, is rapid, and resulted in increased 
virion recovery.  
Although this alternative method, to our knowledge, has never been used for RSV cell lysis, 
since AMPV is similar to RSV in being a non-segmented, single-stranded, RNA virus that 
belongs to the Paramyxoviridae family, this suggested it could be applicable for our purpose 
of RSV recovery. We used this hypotonic lysis method as a pre-inoculation step for optimal 
TCF cultivation. The optimised cell lysis protocol was carried out as follows: Stored viral 
supernatant from 2nd line SV culture was added to 15 ml centrifuge tubes and incubated at 
room temperature with 5 ml of Milli-Q H2O for 15 minutes. Cells were lysed by repeated 
pipetting for 30 seconds per minute of incubation (15 times), after which cellular rests were 
collected by centrifugation at 3000 x g for 15 minutes. The viral supernatant, containing a 
large quantity of cell-free virions, was transferred to new 15 ml centrifuge tubes, and mixed 
by vortexing for 1 minute with an equal volume (5ml) of 4% MEM (2 ml of 10% MEM with 3 
ml Milli-Q H2O) to restore original stock tonicity. The virus medium was then treated with 25% 
sucrose solution as before and stored at 4°C for TCF inoculation. 
Lastly, the final step of culture optimisation, involved cultivating RSV in TCF seeded with the 
CoHM cell line mixture, applied from the successful SV culture method, instead of HEp-2 
cells only. Briefly, 75 cm2 TCF were readied for viral inoculation as before, but prepared with 
a CoHM cell suspension, with each cell type seeded at 15 x 104 cells/ml, and added in equal 
amounts. TCF were inoculated with stored 2nd line SV supernatants, incubated, and IMF 
confirmation done as before. After confirmation of successful TCF growth (sufficient for 
preparation of viral standards), harvested cell suspensions were stabilised with 25% sucrose 
solution. Final RSV stock to be used for titration and RNA extraction was stored as 1 ml 
aliquots at 4°C, whilst remaining stock was preserved as 15 ml aliquots at -80°C. 
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2.2.6 Viral quantification 
Accurate and effective viral titration forms the core of a reliable standard utilised in assay 
development and evaluation. Traditional titration methods have relied on ubiquitous plaque 
reduction assays or CPE based reduction assays;95 with titre usually expressed as plaque 
forming units per ml (PFU/ml) or tissue culture 50% infectious dose per ml (TCID50/ml). Such 
reduction assays for RSV titration are time-consuming (taking at least 5-7 days for CPE 
observation),96 require costly reagents, and are cumbersome to perform. Several rapid 
techniques have been reported; based on monitoring changes in absorbance,97 colorimetric 
detection,98 or viral neutralising antigen expression,99 which render continuous rather than 
orthodox quantal data, and use automated equipment with advanced computational 
software.100, 101 However, the high throughput nature of these methods limits their generalised 
use. 
Domachowske and Bonville (1998) developed a SV fluorescent-focus assay as an efficient, 
more timely, and easily performed alternative, that correlates well to standard plaque 
assays.102 This method was adopted for our RSV titration purposes as follows: Convalescent 
foci are problematic at low dilutions; therefore, to find the optimal linear range which would 
allow accurate quantification, serial two-fold dilutions (1:100, 1:200, 1:400, 1:800, 1:1600, 
1:3200) were made of the RSV A and B culture-derived stock. The dilutions were prepared in 
RPMI-1640 medium as 1 ml aliquots, of which 200 μl from each dilution was inoculated onto 
readied shell vials, incubated and mAb/FITC stained as before. Enumeration of fluorescent 
cells was done manually by IMF microscopy, each fluorescent focus representing 1 
infectious unit of RSV, with the titre expressed as focus forming units per ml (FFU/ml). The 
SV titration assay was done in triplicate for both RSV genogroups.     
2.2.7 RNA extraction and preservation 
Extraction of RSV RNA to be used as standards for development and optimisation of the 
RSV RT-LAMP assay, was performed using the NucliSENS® easyMAG® platform 
(bioMérieux, Boxtel, The Netherlands), according to manufacturer specifications. The 
NucliSENS easyMAG is an automated nucleic acid (NA) isolation system, utilising magnetic 
silica extraction technology,103 and produces optimally recovered NA extracts, free of 
amplification inhibitors.104   
Briefly, two-fold serial dilutions (that mirror the titration dilutions and prevents sample 
oversaturation) of RSV A and B stock were prepared in MEM maintenance medium as 1 ml 
aliquots, with 750 μl of each dilution used as input volume. Samples are directly lysed on-
board for 10 min in Boom lysis buffer containing 5 M guanidinium thiocyanate, after which 50 
μl of silica suspension was added manually to all extraction wells and homogenised 
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thoroughly for RNA adsorption. The silica matrix then underwent a series of washing steps in 
buffers with high salt concentration to purify the RNA, followed by a heating step at 70°C to 
release the RNA from the silica. Lastly, 50 μl of purified RNA from each input sample was 
eluted, and transferred to clear 0.2 ml Axygen® PCR tubes (Corning, New York, USA) that 
were kept on ice for same day preservation.  
RNAstable® (Biomatrica, San Diego, USA) was used for long term storage of RNA standards, 
allowing anhydrous preservation at ambient temperature, without use of cold storage, thus 
preventing RNA degradation associated with freezing. Briefly, 10 μl aliquots (dilutions of 100, 
101, 102, 103, and 104) of extracted RSV A and B RNA were each resuspended in 10 μl of 
nuclease-free water (Qiagen, Hilden, Germany). The 20 μl suspensions were added to 
RNAstable 96-well plates, mixed gently by pipetting, placed under a laminar flow cabinet to 
air dry overnight for 12 hours, and once air dried, samples were stored in a dark, non-humid 
area. Sample recovery only requires re-suspension with nuclease-free water (10 μl for 
original concentration), and is ready for downstream assays without further purification.  
2.3 Primer design 
The LAMP technique uses four specially designed primers that discern six distinct regions on 
the target RNA;78 these characteristics make it a highly specific and sensitive method for 
gene amplification, however, the caveat to this efficient amplification are the challenges 
regarding primer design. The inherently AT-rich RSV genome,105 along with limited sequence 
conservation due to the genetic variability among the two antigenic RSV genogroups,106 
prove problematic for multiplex primer design. Further important considerations that add to 
the intricacy of LAMP primer design are the varying distances required between primer 
regions, the primer melting temperature (Tm), and stability of primer ends. 
A single set of 8 multiplex LAMP primers (see Table 1) to encompass both RSV A and B 
were designed to target a highly conserved region on the RSV L polymerase gene. 
Conserved regions in the genogroups were identified by whole genome alignment of a range 
of reference strains extending the main RSV group A and RSV group B genotypes. The 
sequences were retrieved from GenBank (see Appendix Table A1), aligned in Geneious 
software suite (version 6.1.3; Biomatters Ltd., Auckland, New Zealand), after which a 
combined RSV genogroup consensus sequence was aligned by ClustalW in Geneious and 
used for primer design.       
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Primers for the RT-LAMP assay were designed in silico using the Primer Explorer web-based 
software tool (version 4; Eiken Chemical Co., Tokyo, Japan),107 and then adjusted manually 
as necessary. Primer sequences were analysed for secondary structure formation with 
OligoAnalyzer (version 3.1; Integrated DNA Technologies, Iowa, USA),108 and on the Basic 
Local Alignment Search Tool (BLAST, NCBI)109 to screen for specificity against any regions 
of similarity to other organisms. Primers were synthesised by Integrated DNA Technologies 
(IDT, Iowa, USA). Outer and loop primers underwent standard desalting, whilst longer inner 
primers were purified by polyacrylamide gel electrophoresis (PAGE) as these longer primers 
are more problematic to bind and require extra purification.  
 
Table 1.  Primer set used in the multiplex RT-LAMP assay. 
Primer                        Tm/GC value        Sequence (5’-3’) 
RSV_F3                               54.4°C/33.9%            AAGCAARTATGTTAGAGAAAGATCTTGG 
RSV_B3                               52.4°C/34.0%            CTCTGYTTTTTGGTTAAAACTTGTC 
RSV_LF                                50.9°C/25.0%            TATATTTGATGTCCATTGTATACATGAT 
RSV_LB                                54.0°C/50.0%            AGAGGACCCACTAARCCAT 
RSV_A_FIP (F1c+F2)          67.0°C/45.6%            TGCCACTAGCTATAGTGCTTGTTGTTGTTGGTGTTACATCACCCAG 
RSV_B_FIP (F1c+F2)          66.1°C/45.6%            TACCACTGGCTATAGTGCTAGTTGTTGTAGGAGTAACATCGCCAAG 
RSV_A_BIP (B1c+B2)         63.9°C/37.7%            TGTCAACAGTTTAACACGTGGTTTTTTCTCTTGTGTAGATGAACC 
RSV_B_BIP (B1c+B2)         64.4°C/38.2%            TGTTAATGGTTTAACTCGTGGTGAATTTTTCTCCTGCGTAGATGAAC 
GC: guanine-cytosine; F3: forward outer primer; B3: backward outer primer; LF: loop forward primer; 
LB: loop backward primer; FIP: forward inner primer consisting of a forward region (F2) and a 
complement region (F1c); BIP: backward inner primer consisting of a backward region (F2) and a 
complement region (B1c).  
To accommodate for sequence diversity across RSV genogroups, degenerate bases were 
used in place of genetically variable bases where necessary. Special attention was given to 
adjust the Tm of primers in the optimal LAMP order i.e., FIP/BIP > F3/B3 > LF/LB. The 
approach with regards to sequence mismatches in the inner primers (FIP and BIP), was to 
design separate inner primers for RSV A and B respectively, so as to mix in a 50:50 ratio; 
this allows matching of one „degenerate‟ with group A and the other with group B, and as the 
designs are very similar except for a few bases, primer dimer reactions would be limited. 
Figure 1 illustrates the multiplex RT-LAMP design.   
Stellenbosch University  https://scholar.sun.ac.za
15 
Figure 1. Positioning of primers in RSV genome. (A) Primers are indicated by boxed sequence; 
primer colour is identical to primers in Table 1; black arrows indicate direction of synthesis; and 
underlined bases are mismatches in sequence alignment. Template derived FIP is a hybrid primer 
consisting of a complementary alignment (F1c) which is linked to F2, and initiates strand elongation by 
converting RNA to cDNA; cDNA amplification occurs likewise with the BIP (B1c and B2). Strand 
displacement cDNA synthesis is primed by outer (F3) primer, producing dsDNA. BIP and B3 primers 
then hybridise to the FIP template cDNA, which produces a stem-loop structure. The loop primers (LF 
and LB) attach to the formed loop and continue DNA synthesis by displacement of the stem-loop. 
Subsequent LAMP cycling involves the FIP binding to the loop product, displacement DNA synthesis 
progresses, resulting in the original stem-loop and an additional longer stem-loop. (B) Schematic 
diagram (not to scale) depicting genes in the RSV genome; block length is in proportion to gene 
length; and the white box indicates the approximate location of the RT-LAMP primer region in the L 
gene. Image redrawn using Geneious software suite (version 6.1.3; Biomatters Ltd., Auckland, New 
Zealand).     
2.4 RT-LAMP reaction 
To obtain optimal reaction conditions specific for the multiplex RT-LAMP primer set, reagent 
concentrations and reaction temperatures were tested as optimisation factors. To save costs, 
an optimised (reagent concentrations adjusted as necessary) in-house reaction mixture (see 
Table 2) was used for all RT-LAMP reactions, instead of the well-known Loopamp® RNA 
Amplification Kit supplied by Eiken (Eiken Chemical Co., Tokyo, Japan), that is widely used 
in LAMP orientated research. Reagent preparation, addition of RNA, and amplification were 
carried out in separate rooms with restricted access and unidirectional workflow. Throughout 
optimisation and validation, each RT-LAMP assay included a non-Template Control (NTC) to 
screen for contamination. All precautions to prevent cross-contamination were observed.  
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Optimisation of reaction temperature and primer concentration was done by running the RT-
LAMP assay at a range of temperatures (59°C, 60°C, 61°C, 62°C, 63°C, and 64°C), and final 
primer concentrations either at (FIP/BIP: 0.4 μM; LF/LB: 0.2 μM; F3/B3: 0.05 μM) or 
(FIP/BIP: 0.8 μM; LF/LB: 0.4 μM; F3/B3: 0.1 μM) in the Veriti® 96-well thermal cycler (Applied 
Biosystems Inc., California, USA). The separate inner primers for RSV A and B were 
combined in a ratio of 50:50 and added in equal amounts to each reaction. All RT-LAMP 
assays were subsequently run at 64°C for 60 minutes (30 second cycles), followed by an 
inactivation step at 80°C for 5 minutes. The RT-LAMP was carried out as a single-step, 
close-tubed reaction, at a final reaction volume of 25 μl in clear 0.2 ml PCR tubes (Corning, 
New York, USA).   
 
Table 2.  Optimised reaction conditions for RSV multiplex RT-LAMP. 
Reagent                                        Final Concentration              Function 
Primers:           FIP                                                 0.8 μM            
                           BIP                                                0.8 μM             
                           LF                                                  0.4 μM 
                           LB                                                  0.4 μM             
                           F3                                                  0.1 μM 
                           B3                                                  0.1 μM            
2X Reaction mix:              
ThermoPol
™
 Buffer:                                              40 mM Tris-HCl                Isothermal amplification polymerase buffer 
                                                                                  20 mM (NH4)2SO4            
                                                                                  50 mM KCl                   
                                                                                  0.2% Tween-20 
MgSO4                                                                     16 mM                                Used for optimum polymerase activity 
DNTPs                                                                      2.8 mM each                     Nucleotides for polymerisation 
Betaine                                                                    1.6 M                                  DNA stabilisation  
Enzymes: 
AMV Reverse Transcriptase                                5U/25 μl                            First-strand cDNA synthesis  
Bst 2.0 WarmStart
™
 DNA Polymerase               8U/25 μl                            Strand-displacement DNA synthesis 
SYBR
®
 Green I                                                         0.5X/25 μl                          dsDNA binding fluorescent dye                                               
Template RNA                                                        5 μl                                       
Nuclease-free H2O                                                 Add to 25 μl                                            
ThermoPol Buffer and Bst 2.0 WarmStart DNA Polymerase: (New England BioLabs Inc., Ipswich, 
USA); MgSO4: (Sigma-Aldrich, St. Louis, USA); DNTPs: (Bioline, London, UK); Betaine: (Sigma-
Aldrich, St. Louis, USA); AMV Reverse Transcriptase: (Promega Corp., Madison, USA); SYBR Green 
I: (Life Technologies, Carlsbad, USA).  
Further RT-LAMP assay optimisation and validation was done in the Corbett Rotor-Gene Q 
6000 real-time thermocycler (Qiagen, Hilden, Germany). Amplification products of the RT-
LAMP assay were analysed using Rotor-Gene Q software (version 1.7.87; Qiagen, Hilden, 
Germany), whereby generated reaction curves (read on FAM channel between 470 nm and 
510 nm) reflect the relative fluorescent intensity over reaction time of the RNA amplification 
products.  
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During optimisation and validation, agarose gel electrophoresis (AGE) was done to confirm 
RT-LAMP results. Briefly, 10 μl of amplicons were mixed with 2 μl GeneDirex® Novel Juice 
dye (Biocom Biotech, Centurion, South Africa) supplied in 6X DNA Loading Buffer, and run at 
80 V for 50 minutes with the PowerPac Basic Power Supply (Bio-Rad, California, USA) on a 
0.8% agarose gel (SeaKem LE Agarose; Cambrex Bioscience, Maine, USA) in 60 ml of 1X 
SB buffer (containing 10 mM NaOH, 28 mM boric acid, at pH 8.5). An O‟GeneRuler™ 1 kb 
DNA Marker (Fisher Scientific, Pittsburgh, USA) was used for amplicon size reference. A 
characteristic ladder pattern can be seen in AGE, since amplicons consist of several inverted 
repeats, ranging in size, of the target sequence on the same strands. Agarose gels were 
visualised by UV fluorescence on the Alliance 2.7 optic analysis system (UViTec, Cambridge, 
UK).  
2.5 RT-LAMP validation 
The optimised RSV multiplex RT-LAMP assay was evaluated using residual laboratory viral 
isolates, by comparing it to the current standard assay used for respiratory viral diagnostics 
in the Division of Medical Virology, Stellenbosch University, which is the Seeplex® RV15 ACE 
multiplex PCR (Seegene, Seoul, Korea). The minimum sample size was calculated as 
follows: Assuming the Seeplex RV15 as gold standard and accepting a sensitivity of at least 
95%, with an alpha of 0.05 and power of 90%, the required sample size for comparison was 
32 specimens.  
We evaluated the RT-LAMP assay against 44 pre-selected RSV positive (22 RSV A and 22 
RSV B) NP specimens tested on Seeplex RV15. All NP specimens were tested in triplicate 
with respective RSV A and RSV B positive controls (50 FFU/reaction) included during the 
RT-LAMP assay. The RNA and DNA of NP specimens and viruses that were used 
throughout validation tests was extracted on the NucliSENS easyMAG system according to 
manufacturer specifications as previously described. 
Analytical sensitivity of the RT-LAMP assay was determined by testing with culture derived 
RSV A and B RNA standards (concentrations of 5, 101, 102, 103, and 104 FFU/reaction) in 
triplicate (repeated twice). The RT-LAMP assay specificity of the multiplex RSV primer set 
was assessed by screening in triplicate RSV standard (104 FFU/reaction) against a panel of 
9 other common respiratory viruses that were positive by Seeplex RV15 and available in our 
laboratory, including, Influenza A and B virus, Human parainfluenza virus (hPIV-1, hPIV-2, 
and hPIV-3), Rhinovirus, Adenovirus, Enterovirus, and Coronavirus 229E. To ascertain the 
reproducibility of the RT-LAMP assay, 3 replicates each of a positive RSV A and RSV B NP 
specimen (with unknown concentration) were tested across two different RT-LAMP runs, with 
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the time to positivity read for each specimen. Both reproducibility runs included RSV A and 
RSV B positive controls (50 FFU/reaction).  
2.6 Confirmation of RSV subgroups 
Differentiation of RSV subgroups was done by restriction enzyme (RE) digestion of RSV RT-
LAMP products as follows: Restriction enzymes were mapped on the RT-LAMP target region 
using the online NEBcutter tool (version 2.0; New England BioLabs Inc., Ipswich, USA).110 
Figure 2 indicates the recognition site for each RE. RT-LAMP products were purified using 
the Wizard® SV PCR Clean-Up System (Promega Corp., Madison, USA) according to 
manufacturer instructions (see Appendix Protocol A1). RSV A amplicons were digested with 
FastDigest™ NlaIII and RSV B with FastDigest™ Hpy8I (Thermo Scientific Inc., Waltham, 
USA) in 30 μl reactions (containing 1 μl RE, 3 μl supplied 10X FastDigest buffer, 1 μl purified 
DNA, and 25 μl nuclease-free H2O). RE reactions were incubated in a heating block at 37°C 
for 2 hours, followed by 5 minute incubation at 80°C to inactivate the RE. Digested RT-LAMP 
products were then separated by AGE and UV visualised as described before, with the 
exception of using a 2% agarose gel ran at 80V for 2 hours, and an O‟GeneRuler™ 100 bp 
DNA Marker (Fisher Scientific, Pittsburgh, USA) for product size reference.  
Figure 2. Design of RE digestion sites for confirmation of RSV subtypes. nb: nucleobases; 
location for the recognition sequence of each RE in the RT-LAMP target region is indicated by 
underlined sequence; and arrows are the defined cleavage site for each RE. (RSV A) Expected 
fragments: 42 nb, 47 nb, 84 nb, 94 nb (cut-off fragments); the definitive fragment between cut sites 
was 180 nb. (RSV B) Expected fragments: 14 nb, 44 nb, 88 nb, 148 nb (cut-off fragments); the 
definitive fragment between cut sites was 296 nb.  
Additionally, the RE design included the single use of Hpy8I for direct digestion of un-purified 
RT-LAMP amplicons. Briefly, RT-LAMP products were directly digested, but with Hpy8I only, 
and visualised as before. If RSV B then the expected definitive fragment would be 296 nb 
(fragment between cut sites), else if RSV A then the expected definitive fragment would be 
88 nb (fragment from single cut site). This would allow diagnostic subtyping of RSV A and B.  
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2.7 Visual detection of RT-LAMP 
As a final step of assay development, the multiplex RT-LAMP assay was optimised to allow 
colorimetric-mediated visualisation of RSV with the naked eye. Hydroxy naphtol blue (HNB) 
is a metal ion indicator that reacts with the large amounts of magnesium pyrophosphate by-
product that forms from a positive LAMP product.82 A recent study reported on the 
applicability of HNB as colorimetric reagent for LAMP detection, and showed the HNB LAMP 
method was associated with reduced contamination risk, compared to other LAMP assays 
using techniques to visualise a reaction result that require opening of tubes, such as for the 
addition of intercalating dyes, for instance AGE.111 Furthermore, the easy and inexpensive 
nature of the procedure makes it versatile for high-throughput diagnostics. 
To monitor the RT-LAMP assay colorimetrically, HNB (Sigma-Aldrich, St. Louis, USA) was 
added to the pre-LAMP reaction mixture, at a final concentration of 120 μM, replacing SYBR 
Green I in equal volume (0.5 μl/25 μl reaction). By replacing the intercalating SYBR Green I 
dye with HNB the Rotor-Gene Q thermocycler cannot be used to read sample positivity as 
HNB does not fall within the absorbance spectrum of the instrument, making a simple water 
bath ideal for PoC use. The RT-LAMP assay with HNB was tested for analytical sensitivity 
and specificity by incubation of culture derived RSV A and B RNA standards (concentrations 
of 101, 102, 103, and 104 FFU/reaction), and against the same panel of 9 other respiratory 
viruses tested during RT-LAMP validation, respectively. The aforementioned samples were 
incubated in a water bath at 64°C for 50 minutes, after which the reactions were inactivated 
at 80°C for 5 minutes in a heating block. The post-LAMP reaction tubes were then assessed 
for positivity by naked eye.  
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Chapter 3: Results  
3.1 Preparation of viral standards 
3.1.1 Cell culture 
To prepare high-titered viral standards for downstream RT-LAMP assays, RSV was 
propagated in cell culture under various conditions, modes of cell culture used, and several 
techniques incorporated in the process, as illustrated by Figure 3.    
 
Figure 3. Cultivation of RSV under different culture conditions. Images were captured by UV IMF 
microscopy; infectious virus was visualised as apple-green fluorescent foci, and uninfected cells 
stained red; the characteristic syncytia formation of RSV can be seen as large aggregations of positive 
foci. (A) 2
nd
 line RSV SV culture in CoHM cell line mixture. (B) TCF culture of RSV grown without any 
optimisation in HEp-2 cell monolayer. (C) TCF culture of sucrose-stabilised RSV, following a pre-
inoculation hypotonic cell-lysis step, grown in CoHM cell line suspension.  
 
The centrifugation-enhanced SV technique was used to produce an initial RSV stock, after 
which adequate quantities of viral stock were cultured in larger TCF. Sufficient RSV 
proliferation that replicated SV growth could not be achieved in TCF culture, subsequently, a 
series of steps were implemented to optimise the whole cell culture process.  
The optimisation of the SV assay by using a double SV passage approach, and a limiting 
dilution method to reduce the effect of increased DIP generated during additional passage, 
yielded high levels of positive RSV growth in SV culture (Figure 3 A). When compared to 
standard TCF culture pre-optimisation (Figure 3 B), RSV propagation in TCF was 
significantly improved through the optimised culture procedure (Figure 3 C), ultimately 
providing the desired high-titre RSV final culture stocks.   
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3.1.2 Viral quantification 
Titration of culture-derived RSV standards was done according to a previously published SV 
IMF assay.102 Table 3 shows the representative data for the experiment at two-fold stock 
RSV dilutions from 1:100 to 1:3200. At the concentrated RSV dilution (1:1) florescent foci 
were too numerous to count, as we suspect infectious foci might be coalescing, leading to 
falsely low-titre results.   
Table 3.  Shell vial fluorescent-focus titration assay of RSV standards. 
TMTC: too many to count; SV number represents respective RSV A and B replicates at each dilution 
which was done in triplicate; * average fluorescent focus units/dilution x dilution factor x 5 fluorescent 
focus units/ml (200 μl per SV).  
The optimal linear range which would allow accurate quantification of RSV culture standards 
was found to be at the two highest dilutions (indicated by red blocks in Figure 4), since there 
was no confluence of fluorescent foci or other factors resulting in lower titres. This might be 
due to the competition factor being minimised at high dilutions, and as these yielded higher 
titres with the lowest difference in absolute value (8000 FFU/ml for RSV A and 26667 FFU/ml 
for RSV B), reading at these concentrations is likely accurate. The high r² value (0.9273) 
indicates the goodness-of-fit of the linear regression data for the experiment.    
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Figure 4. Lines of unity and scatter plots of RSV SV titration assay. Data of fluorescent focus 
units/ml is of the available 18 RSV A and 9 RSV B dilution replicates; red blocks are the data points 
reflecting the two highest dilutions of respective linear sets.   
 
As the optimal linear range of quantification was shown to be at the highest dilutions in the 
RSV A titration assay, only the three highest dilutions (1:800, 1:1600, and 1:3200) were used 
for RSV B titration.  
 
3.2 RT-LAMP reaction  
The RT-LAMP assay was optimised by testing the designed multiplex primer set with an in-
house reaction mix under different reaction conditions, with results confirmed by AGE (see 
Figure 5).     
 
Figure 5. Testing of optimisation factors in the RT-LAMP assay. A: RSV A standard (10
3
 
FFU/reaction); B: RSV B standard (10
3
 FFU/reaction); N: non-Template control. (A) Reaction 
temperature optimisation; Lane 1: 1 kb O‟GeneRuler DNA marker; Lane‟s 2-4: 59°C; Lane‟s 5-7: 60°C; 
Lane‟s 8-10: 61°C; Lane‟s 12-14: 62°C; Lane‟s 15-17: 63°C; Lane‟s 18-20: 64°C. (B) Primer 
concentration optimisation at 64°C; Lane 1: 1 kb O‟GeneRuler DNA marker; Lane‟s 2-4: (FIP/BIP: 0.8 
μM; LF/LB: 0.4 μM; F3/B3: 0.1 μM); Lane‟s 5-7: (FIP/BIP: 0.4 μM; LF/LB: 0.2 μM; F3/B3: 0.05 μM).               
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The RT-LAMP multiplex primer set successfully amplified template RSV RNA with the in-
house reaction mix across all annealing temperatures (Figure 5 A) and primer concentrations 
(Figure 5 B). The optimal annealing temperature was deemed to be 64°C, and a final primer 
concentration at (FIP/BIP: 0.8 μM; LF/LB: 0.4 μM; F3/B3: 0.1 μM), as these reaction 
conditions produced the highest amount of amplified product (see Figure 5), and shortest 
reaction time (see Figure 6).  
Figure 6 illustrates visualisation of time to positivity for amplification products on the Corbett 
Rotor-Gene Q, and represents the experiment to optimise RT-LAMP primer set 
concentration. The instrument was programmed to use cycles of 30 seconds as reaction time 
as this provides a more efficient acquisition of fluorescence data for the LAMP reaction. 
Positive samples could be clearly distinguished from negative samples, as reaction curves of 
positives exhibit a distinct exponential phase of amplification, compared to the continual lag 
phase of negative reaction curves with non-specific fluorescence well below the plateau of 
positives (see Figure 6).  
Figure 6. Real-time reaction curves of RT-LAMP primer concentration optimisation. The x-axis 
refers to reaction time (cycles of 30 seconds), and the y-axis refers to relative fluorescent intensity; 
colours of the reaction curves correspond to sample legend; RT-LAMP reaction was run at 64°C; A: 
RSV A template (10
3
 FFU/reaction); B: RSV B template (10
3
 FFU/reaction); NTC: non-Template
control; Set 1: Primer concentration at (FIP/BIP: 0.8 μM; LF/LB: 0.4 μM; F3/B3: 0.1 μM); Set 2: Primer 
concentration at (FIP/BIP: 0.4 μM; LF/LB: 0.2 μM; F3/B3: 0.05 μM). Time to positivity: Set 1-A (13 
minutes) vs. Set 2-A (32 minutes), Set 1-B (30 minutes) vs. Set 2-B (52 minutes).  
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3.3 RT-LAMP validation 
3.3.1 Clinical specimen evaluation 
The performance of the optimised multiplex RT-LAMP assay to detect RSV was assessed 
against positive laboratory viral isolates (22 RSV A and 22 RSV B) previously tested by 
Seeplex RV15 PCR. The data generated by RT-LAMP evaluation is shown in Table 4.    
Table 4.  Amplification times for RSV positive specimens evaluated by RT-LAMP. 
Specimen Specimen
A1 17:00 B1 29:30
A2 11:00 B2 23:00
A3 14:30 B3 29:00
A4 33:45 B4 25:30
A5 30:30 B5 26:00
A6 21:45 B6 31:15
A7 12:30 B7 39:30
A8 15:00 B8 36:30
A9 16:00 B9 48:20
A10 17:00 B10 24:30
A11 13:30 B11 28:45
A12 14:15 B12 30:00
A13 15:00 B13 32:45
A14 13:00 B14 22:00
A15 16:15 B15 21:15
A16 18:30 B16 18:00
A17 20:00 B17 17:30
A18 15:30 B18 17:15
A19 14:00 B19 15:30
A20 13:15 B20 18:00
A21 12:45 B21 25:45
A22 13:00 B22 36:15
Mean Amplification 
Time (min:sec) 
Mean Amplification 
Time (min:sec) 
Specimens are named according to respective RSV A and B specimens and the number of each 
tested (22 RSV A and 22 RSV B); mean amplification time is of the three replicates of each positive 
RSV specimen tested in triplicate by RT-LAMP.  
Of the 22 RSV A isolates that were positive by Seeplex RV15, all 22 were positive by RT-
LAMP, and of the 22 RSV B isolates that were positive by Seeplex RV15, all 22 were positive 
by RT-LAMP. Thus, the multiplex RT-LAMP assay had a sensitivity of 100% for detecting 
RSV (44/44). The mean amplification time for the 22 pre-selected RSV A positives was 16.7 
minutes (ranging between 11 and 33.75 minutes; 95% CI 14.2-19.1 minutes), and the mean 
amplification time for the 22 pre-selected RSV B positives was 27 minutes (ranging between 
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3.3.3 Primer specificity  
The RSV RT-LAMP primer set specificity was screened in triplicate against residual 
laboratory isolates of 9 other common respiratory viruses that were positive by Seeplex 
RV15 PCR. According to the results of the RT-LAMP, the multiplex RSV primer set only 
amplified RSV template, and did not react with other respiratory viruses (see Figure 9). 
Therefore, the multiplex RT-LAMP assay was 100% specific for detecting RSV.    
 
 
Figure 9. Reaction specificity of multiplex RT-LAMP primer set. Other viruses are the non-RSV 
respiratory viruses which include FB: Influenza B; RV: Rhinovirus; PI3: Parainfluenza-3; CV: 
Coronavirus 229E; PI1: Parainfluenza-1; AV: Adenovirus; PI2: Parainfluenza-2; EV: Enterovirus; FA: 
Influenza A. NTC: non-Template control. (A) Real-time differentiation of RT-LAMP primer specificity; 
the x-axis refers to reaction time (cycles of 30 seconds), and the y-axis refers to relative fluorescent 
intensity; RSV standard is 10
4
 FFU/reaction. (B) Confirmation of real-time results by AGE; 1kbM: 1 kb 
O‟GeneRuler DNA marker; RSV: RSV standard (10
4
 FFU/reaction).  
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3.3.4 Reproducibility 
The repeatability of the RT-LAMP assay was determined by testing 3 replicates over two 
separate RT-LAMP runs for each RSV subgroup from respective NP specimens that were 
positive by Seeplex RV15 and subsequently RT-LAMP. Time to positivity data of the 
experiment is shown in Table 5.  
Table 5.  Reproducibility of RT-LAMP testing. 
Specimens are named according to respective RSV A and B 
replicates and the number of each tested. 
The mean amplification time for the 3 RSV A replicates across both runs was 14.33 minutes 
(with amplification times within 2 minutes for each replicate; mean SD 0.74 minutes), and the 
mean amplification time for the 3 RSV B replicates across both runs was 38.79 minutes (with 
amplification times within 8.75 minutes for each replicate; mean SD 3.58 minutes).  
The coefficient of variation (CV) for the respective subgroup replicates was very low and 
similar (5.1% for RSV A and 9.2% for RSV B), suggesting the multiplex RT-LAMP assay was 
highly reproducible for both RSV subgroups.  
3.4 Confirmation and subtyping of RSV subgroups 
The RSV subgroups were classified by RE digestion of RT-LAMP products. RSV A 
amplicons were digested with FastDigest NlaIII and RSV B with FastDigest Hpy8I. 
Furthermore, the RE design was such that Hpy8I could be utilised exclusively for direct 
digestion of un-purified RT-LAMP amplicons, which would enable diagnostic subtyping of 
RSV A and B. Results of the RE digestion experiment were confirmed by AGE (see Figure 
10). 
Run 1 Run 2
A1 14:00 14:30
A2 13:15 14:00
A3 15:15 15:00
B1 35:45 42:30
B2 34:15 39:45
B3 37:30 43:00
Amplification Time 
(min:sec) 
Specimen
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Figure 10. Electrophoresis of RT-LAMP products after RE digestion. M: O‟GeneRuler 100 bp 
DNA marker; A: RSV-A; B: RSV-B; A-P: RSV-A Purified; B-P: RSV-B Purified; A-UP: RSV-A Un-
purified; B-UP: RSV-B Un-purified; BD: Before Digestion; AD: After Digestion; nb: nucleobases; white 
arrows indicate size reference of definitive bands for respective digestions.     
Un-digested RT-LAMP products presented with the prominent ladder pattern of DNA 
amplicons, whilst they formed one major band with smaller minor bands post-digestion. The 
expected 180 nb definitive fragment, specific for NlaIII RSV A digestion, was clearly 
distinguishable from the expected 296 nb definitive fragment specific for Hpy8I RSV B 
digestion (see Figure 10 A). RSV subgroup differentiation was possible from un-purified 
digestion using Hpy8I only, with RSV A forming a definitive band of 88 nb, compared to the 
296 nb definitive band of RSV B (see Figure 10 B).   
3.5 Visual detection of RT-LAMP 
Hydroxy naphtol blue was added to the pre-LAMP reaction mixture as colorimetric indicator 
to allow for visual diagnosis of RSV by RT-LAMP in a water bath. The run time of the HNB 
RT-LAMP assay should be set at 50 minutes, since it corresponds to the upper range of time 
to positivity determined in clinical specimen testing, followed by 5 minutes inactivation of 
reaction enzyme to prevent further amplification. The post-LAMP reaction tubes could be 
monitored for positivity by the naked eye in good ambient light conditions (optimally on a light 
box), with a positive reaction indicated by a change of violet (pre-amplification) to the 
characteristic sky blue colour, as illustrated in Figure 11 and Figure 12.  
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The RT-LAMP assay could detect over four logs of culture derived standard FFU for both 
RSV subgroups (see Figure 11), and was negative for all 9 other respiratory viruses 
screened against, whilst only being reactive for respective RSV subgroups (see Figure 12). 
Thus, visual detection of RSV using HNB as colorimetric reagent was equivalent to the 
analytical sensitivity (10 FFU/reaction) and specificity (100%) of the multiplex RT-LAMP 
assay.    
 
Figure 11. Visual detection sensitivity of RT-LAMP assay using HNB for detection of RSV 
subgroup A and B standards. NTC: non-Template control; indicated numbers are the RSV 
standards concentration of 10
n
 FFU/reaction; the colour changes from violet (negative reaction) to sky 
blue (positive reaction). 
 
 
 
Figure 12. Reaction specificity of RT-LAMP assay with HNB for visual detection. Concentration 
of RSV A and B standards is 10
4
 FFU/reaction; negative reactions are violet colour and sky blue 
colour indicates positive reactions; NTC: non-Template control.  
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Chapter 4: Discussion 
4.1 Rationale and main finding 
The past 10 years has seen conventional methods for RSV detection being replaced by more 
sensitive molecular methods. Virus isolation is labour intensive and slow to provide results, 
whilst enzyme or immunofluorescent antigen detection-based tests lack appropriate 
diagnostic sensitivity and specificity. Routinely used nucleic acid-based molecular techniques 
such as RT-PCR and q-PCR produce more definitive diagnostic results with faster 
performance, but require specialised facilities and expensive equipment. RT-LAMP offers a 
robust and simpler to perform diagnostic alternative, with excellent time to diagnosis, and 
without the need for costly thermocyclers or fluorescent probes, making it highly versatile and 
ideal for use at PoC.  
This study describes a highly sensitive, specific, and reproducible molecular isothermal 
diagnostic method for the rapid and simultaneous detection of both RSV subgroups using an 
optimised, novel RT-LAMP assay with a single multiplex primer set, that can be run in a 
standard water bath or heating block. The RT-LAMP assay developed in this study had an 
analytical sensitivity of <10 FFU/reaction, specificity of 100%, and could qualitatively detect 
RSV in all clinical NP specimens tested (n = 44) within 60 minutes (compared to 90-120 
minutes by PCR), with a mean time to positivity for all specimens (RSV A and B) of 21.85 
minutes (95% CI 19.2-24.5 minutes).  
The RT-LAMP assay was further developed to provide definitive, cost-efficient differentiation 
and diagnostic typing of RSV subgroups within 4 hours, following direct restriction enzyme 
(RE) digestion and agarose gel electrophoresis (AGE) visualisation, thereby removing 
reliance on high-priced methods such as genome sequencing. As final element of assay 
optimisation, HNB was used to enable easy visual colorimetric-mediated multiplex RSV 
detection, which matched RT-LAMP analytical sensitivity and specificity, with specific aim 
towards improving PoC applicability for wide use in resource-limited settings, especially 
developing countries. 
The rapid and accurate detection of RSV provided by the multiplex RT-LAMP assay 
developed in this study could significantly improve the effective management and treatment 
of patients, helping to decrease disease morbidity and mortality associated with RSV ALRTI. 
Furthermore, timely diagnosis would aid public health authorities in drawing up appropriate 
plans for prevention and infection control strategies to protect high risk individuals during an 
outbreak, and limit unnecessary or potentially harmful antibiotic use.  
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4.2 RT-LAMP in context 
Despite the advent of isothermal amplification methods being employed more regularly than 
classical laboratory methods for diagnosis of respiratory viruses since the early 2000‟s,112, 113 
a limited number of isothermal amplification tests have been developed for RSV detection, 
with varying clinical and PoC usefulness. A commercial nucleic acid sequence-based 
amplification (NASBA) assay by bioMérieux, the NucliSENS EasyQ RSV A+B NASBA, has 
been reported to compare favourably to culture, IF and PCR methods with detection of RSV 
A and B ranging from 95-20 copies/reaction.114, 115  
Furthermore, only four reports have described the use of RT-LAMP to detect RSV. Ushio et 
al. (2005) used separate singleplex RT-LAMP assays to detect the RSV genome targeting 
the N protein, with amplification taking 1 hour and an analytical sensitivity of 4 and 12 
TCID50/ml for RSV A and B respectively.
116 However, this study only validated specificity for 
RSV detection against 3 influenza virus strains. In comparison, we tested our multiplex RT-
LAMP primer specificity against a varied panel of 9 other respiratory viruses, with detection 
of RSV only. In 2007, Shirato et al. could detect 102 copies/reaction of RSV A and B from the 
M gene by singleplex RT-LAMP assays.117 Both these studies used a limited number of RSV 
genome sequences, 2 and 6 respectively for primer design, possibly compromising the 
coverage of RSV detection. In contrast, our RT-LAMP primer design strategy focused on 
using a range of the most frequently isolated RSV genotypes, with at least 14 different 
reference strains in order to ensure that the design would enable amplification of diverse 
RSV strains. 
Recently, Mahony et al. (2013) and Mu et al. (2014) developed multiplex RT-LAMP assays 
for RSV detection.118, 119 These two reports, together with the abovementioned singleplex-
based studies, all used two separate RSV group A and B-specific primer sets of 6 primers 
each (12 primers in total), with the two multiplex-based studies simply combining primer sets 
for simultaneous RSV detection. Herein, the multiplex RT-LAMP assay developed in our 
study differs, since primer design is based on a novel single set of 8 primers targeting the L 
gene of RSV with only inner primers being a mixture of 2 primer sets, to accommodate 
divergence between RSV A and B.  
This approach of primer design allowed true multiplex detection of both RSV subgroups 
regardless of the inherent challenges of RSV LAMP primer design (e.g. limited sequence 
conservation, amount of primers involved, and thermodynamic requirements). The use of a 
single primer set for concurrent detection of RSV A and B is an important factor for PoC 
applicability in low-resource settings, as it reduces the cost and simplifies ease of use for the 
assay. 
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The analytical sensitivity (<10 FFU/reaction) and rapid amplification (mean amplification time 
of 21.85 minutes for RSV A and B) of our multiplex RT-LAMP assay were either better than 
these earlier RSV RT-LAMP assays or comparable (Mahony et al., 2013). A cost-effective in-
house reaction mix was used, with the choice of enzyme mix particularly influencing 
dynamics of RT-LAMP amplification. Heterodimeric AMV-RT is ideal for cDNA synthesis in 
RT-LAMP, which requires high reaction temperatures, due to its high RNase H activity and 
intrinsic thermal stability.120 For optimal DNA strand-displacement, we used the improved Bst 
2.0 WarmStart DNA polymerase, which amplifies significantly faster with increased yield 
compared to standard Bst DNA polymerase, and its warm start feature solves the problem of 
undesired enzyme activity during reaction setup.121  
When evaluating the reliability and utility of a multiplex diagnostic assay, it is important to 
achieve highly similar analytical sensitivities for respective subgroups. The multiplex RT-
LAMP assay in this study had equal analytical sensitivity for both RSV subgroups, whereas 
Mu et al. (2014) reported a large difference in detection sensitivity (1.58 TCID50/ml for RSV B 
and 281.17 TCID50/ml for RSV A). This might result in an amplification bias, which may 
explain the striking difference in the proportion of NP specimens that tested positive for RSV 
in their study (of 36 positives sequenced, 11 were RSV A vs. 25 RSV B), which could imply 
false-negatives in the overall 77 NP specimens tested by their RT-LAMP assay.  
Of the 4 previous RSV RT-LAMP studies, only one (Mu et al., 2014) developed visual 
colorimetric detection for confirmation of positive RSV (using calcein), whilst Ushio et al. 
(2005) and Shirato et al. (2007) used an expensive real-time turbidimeter and Mahony et al. 
(2013) measured standard real-time fluorescence in a PCR system. Goto et al. (2009) 
showed visual detection of LAMP products using HNB to be a simple, easy to operate and 
diagnostically versatile alternative to other methods, with HNB LAMP assay sensitivity equal 
(160 λ DNA copies/reaction) to an assay using SYBR Green and superior to a calcein-based 
assay (10 times lower).111 Naked eye detection of RSV in our RT-LAMP assay using HNB 
matched the performance indicators of the RT-LAMP by Rotor-Gene Q fluorescent detection, 
and results of the HNB assay can be read for at least 2 weeks, as the colours of HNB in 
positive/negative LAMP reactions remain stable over this time,111 adding to the suitability for 
PoC diagnosis.   
4.3 RSV standards and secondary findings 
A stable and high-titred RSV standard is essential for development, quality control, and 
ensuring a reproducible diagnostic assay. The thermolability and cell-bound replication of 
RSV makes in vitro culture notoriously slow and difficult. Lack of laboratory ATCC RSV 
standards required propagation of RSV from older residual viral isolates that had been 
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subjected to several F-T cycles through previous diagnostic testing, greatly reducing the 
quantity of infectious particles. A centrifugation-enhanced SV technique was used to produce 
highly-infectious seed stocks for TCF proliferation and combined with immunofluorescent 
microscopy for positive RSV visualisation, negating the need for CPE observation and 
resulting in rapid, cost-effective detection of infectious RSV within 48 hours. 
Sufficient RSV growth comparable to SV culture could not be replicated in TCF, 
necessitating several steps to optimise the cell culture process. By implementing a double-
passage SV approach, and using limiting dilutions during sub-passage to nullify the effect of 
possible DIP, a more potent yield of RSV seed stock for TCF culture was achieved. TCF 
were inoculated with 25% sucrose-stabilised viral supernatant that was subjected to 
hypotonic lyses. Hypotonic water lysis of viral supernatant provided simple, effective virion 
recovery from cells in 15 minutes and averts possible loss of virus titre, as is the case with F-
T virus collection which is time-consuming and undergoes regular temperature change. 
Furthermore, as an adaptation from the SV assay, RSV was cultivated in TCF in a CoHM cell 
line mixture, which is thought to be useful for rendering a more accommodating growth 
environment with respect to different RSV genotypes. The incorporation of these optimisation 
steps into the culture process significantly improved RSV isolation frequency in vitro and 
produced a stable and high-titred RSV preparation. 
Although the SV fluorescent-focus titration method required manual counting of fluorescent 
foci, this is offset by allowing timely (within 48 hours) and accurate quantification (i.e., high 
correlation, r² = 0.9273, of optimal linear regression data) of RSV culture standards, the low 
cost of reagents involved, making it more useful in resource-poor settings, as opposed to 
conventional enumeration by laborious reduction assays where culture takes long and CPE 
is often difficult to observe. Lastly, an important factor is long-term storage of the RNA 
standards, which was done through anhydrous preservation at room temperature, ensuring 
RNA integrity was maintained during assay development and validation.  
We strongly believe our findings suggest the culture techniques, optimisation process, and 
titration method used in the cell culture phase of this study, as an integrated approach, could 
be valuable for preparing reliable, quantified viral standards that can be used for the 
optimisation of molecular assays. In addition, this approach could lend itself to modification 
for culture of other paramyxoviruses and cell-associated viruses that are known to be difficult 
to isolate in the laboratory. 
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4.4 Study limitations 
The high rate of nucleic acid amplification products generated by the LAMP reaction, which 
results in the excellent sensitivity and specificity associated with the method, does come with 
some inherent caveats to consider. The LAMP technique requires careful contamination 
control and hence a certain level of training; this may be addressed through standard good 
laboratory practice, such as inclusion of NTCs during assay runs and unidirectional workflow 
throughout reaction setup. Furthermore, the use of AMV RT and addition of HNB pre-
amplification permits single-tube RT-LAMP, thus allaying concerns of cross-contamination. 
The high amplification nature of LAMP may also be associated with background 
amplification, which necessitates the assay to be stopped at a determined time to ensure 
prevention of false positives. This may be a superficial limitation however, easily negated by 
a well-established reaction cut-off time based on assay validation (as in this study), and its 
function as a rapid diagnostic assay.  
We did not validate the multiplex RT-LAMP assay against rare RSV genotypes, but as our 
primers virtually cover the full spectrum of RSV through an approach of targeting several 
reference strains, added to the use of degenerate bases that allows flexibility to molecular 
variation, it is likely that our multiplex primer set will bind these outlier genotypes. Lastly, 
since old residual laboratory specimens were used for RT-LAMP validation, it should be 
noted that the availability of freshly acquired specimen could result in even faster assay 
times, as would be the case when the assay is used as intended for clinical diagnosis.  
4.5 The way forward 
The development of this RSV RT-LAMP assay provides a foundation to explore several 
options of future research. The primary goal is the implementation of the RT-LAMP assay as 
a diagnostic test at the PoC in a resource-limited setting, followed by the possible 
commercialisation of the method. Such purpose requires a rigorous assessment of various 
key measures of success and usefulness of a diagnostic test for PoC. The reliability and 
accuracy of the RT-LAMP assay would have to be tested in the PoC setting and location for 
which it is intended, as performance charateristics of a PoC diagnostic test may differ in a 
clinical setting compared to a controlled laboratory environment.122 To ascertain the 
applicable effect on patient-centred outcomes and ensure effective intervention, study in 
which RT-LAMP PoC testing is prospectively compared to laboratory testing could be a 
valuable indicator for PoC utility.123  
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The simplicity and isothermal nature of LAMP warrants the development of a low-tech 
thermal device conducive to RT-LAMP that can be used in low-resource settings, and which 
may be more practical for PoC application due to enhanced portability compared to a bulky 
water bath or even a heating block. For example, one study investigated the performance of 
non-instrumented nucleic acid (NINA) heaters for amplification of HIV-1 by RT-LAMP, based 
on the chemical exothermic reaction of calcium oxide in customised stainless-steel 
canisters.124   
One challenge to rapid detection of RSV from a respiratory specimen using molecular assays 
is the necessity to first purify RNA, in order to remove RNAses and factors that could inhibit 
PCR. This process is time consuming and requires additional equipment and reagents. A 
simplified extraction method such as boiling has been used for DNA viruses and PCR has 
been successful from whole blood when the pH of buffers was increased in order to limit 
enzyme inhibition.125 Therefore, exploration of simplified extraction methods that would 
precede RSV RT-LAMP could significantly enhance time-to-diagnosis for PoC testing.  
Finally, to determine if RT-LAMP PoC testing would constitute good value, a comprehensive 
cost analysis encompassing all the above-mentioned factors should be done, based on an 
individual RT-LAMP diagnostic test at PoC.  
4.6 Conclusions 
RSV is an important contributor to the global health burden of ALRTI in the young and 
elderly. Early diagnosis of RSV infection is associated with shorter periods of hospitalisation 
and decreased mortality, necessitating rapid and sensitive PoC tests. This study described 
the development of a novel single-step multiplex RSV RT-LAMP assay with excellent 
sensitivity, specificity, and when combined with HNB dye could provide accurate visual 
diagnosis within 1 hour. Various methods and approaches were implemented throughout 
assay development and validation to improve ease of use, cost-efficiency and to streamline 
the end-to-end process for resource-limited use. The LAMP platform allows much scope for 
future development. We envisage that this multiplex RSV RT-LAMP assay will be used for 
rapid and sensitive RSV detection to challenge the current legacy of RSV diagnosis at the 
PoC.  
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Appendices: 
Table A1. GenBank accession numbers of used RSV genomes. 
Group           Accession number     Strain/Genotype 
  JX015498   GA2 
  JQ901449  GA5 
  JF920062   GA7 
  AY911262     ATCC VR-26 (Long) 
  M74568   A2 
A  U39662    S2 
  NC_001803   RSS-2 
  FJ948820   98-25147-X 
  JX627336   GN435 
  FJ614813  Line 19 
B  AF013254    Wildtype B1 
  AY353550   9320 
  JN032116   B/WI/629  
  JQ582843.1  NH1125 
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Protocol A1. Wizard SV clean-up of RT-LAMP amplification products. 
Processing LAMP Amplifications: 
1. Add an equal volume of Membrane Binding Solution to the LAMP amplification.
Binding of DNA: 
2. Insert SV Minicolumn into Collection Tube.
3. Transfer prepared LAMP product to the Minicolumn assembly. Incubate at room
temperature for 1 minute. 
4. Centrifuge at 16,000 × g for 1 minute. Discard flow-through and reinsert Minicolumn into
Collection Tube. 
Washing: 
5. Add 700 μl Membrane Wash Solution (ethanol added). Centrifuge at 16,000 × g for 1
minute. Discard flow-through and reinsert Minicolumn into Collection Tube. 
6. Repeat Step 4 with 500 μl Membrane Wash Solution. Centrifuge at 16,000 × g for 5
minutes. 
7. Empty the Collection Tube and re-centrifuge the column assembly for 1 minute with the
microcentrifuge lid open (or off) to allow evaporation of any residual ethanol. 
Elution: 
8. Carefully transfer Minicolumn to a clean 1.5 ml microcentrifuge tube.
9. Add 50 μl of Nuclease-Free Water to the Minicolumn. Incubate at room temperature for 1
minute. Centrifuge at 16,000 × g for 1 minute. 
10. Discard Minicolumn and store DNA at 4°C or -20°C.
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Appendix A1. Real-time reaction curves of RT-LAMP primer concentration 
optimisation. 
Raw Data For Cycling A.Green 
 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
RSV-A2 (10^3) Standard  1000 
2 
 
RSV-B2 (10^3) Standard  1000 
3 
 
NTC2 NTC   
4 
 
RSV-A1 (10^3) Standard  1000 
5 
 
RSV-B1 (10^3) Standard  1000 
6 
 
NTC1 NTC   
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Appendix A2. Rotor-Gene Q curves for RSV positive specimens evaluated by RT-
LAMP.   
Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
A-Control Standard  50 
2 
 
A-Control Standard  50 
3 
 
A-Control Standard  50 
4 
 
A1 Unknown   
5 
 
A1 Unknown   
6 
 
A1 Unknown   
7 
 
A2 Unknown   
8 
 
A2 Unknown   
9 
 
A2 Unknown   
10 
 
A3 Unknown   
11 
 
A3 Unknown   
12 
 
A3 Unknown   
13 
 
A4 Unknown   
14 
 
A4 Unknown   
15 
 
A4 Unknown   
16 
 
A5 Unknown   
17 
 
A5 Unknown   
18 
 
A5 Unknown   
19 
 
NTC NTC   
20 
 
NTC NTC   
21 
 
NTC NTC   
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Raw Data For Cycling A.Green 
No. Colour Name Type Ct 
1 A6 Unknown 
2 A6 Unknown 
3 A6 Unknown 
4 A7 Unknown 
5 A7 Unknown 
6 A7 Unknown 
7 A8 Unknown 
8 A8 Unknown 
9 A8 Unknown 
10 A9 Unknown 
11 A9 Unknown 
12 A9 Unknown 
13 A10 Unknown 
14 A10 Unknown 
15 A10 Unknown 
16 NTC NTC 
17 NTC NTC 
18 NTC NTC 
Stellenbosch University  https://scholar.sun.ac.za
41 
Raw Data For Cycling A.Green 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 A-Control Standard 50 
2 A-Control Standard 50 
3 A-Control Standard 50 
4 A11 Unknown 
5 A11 Unknown 
6 A11 Unknown 
7 A12 Unknown 
8 A12 Unknown 
9 A12 Unknown 
10 A13 Unknown 
11 A13 Unknown 
12 A13 Unknown 
13 A14 Unknown 
14 A14 Unknown 
15 A14 Unknown 
16 A15 Unknown 
17 A15 Unknown 
18 A15 Unknown 
19 A16 Unknown 
20 A16 Unknown 
21 A16 Unknown 
22 NTC NTC 
23 NTC NTC 
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No. Colour Name Type Ct Given Conc (copies/reaction) 
24 
 
NTC NTC   
Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
A-Control Standard  50 
2 
 
A-Control Standard  50 
3 
 
A-Control Standard  50 
4 
 
A17 Unknown   
5 
 
A17 Unknown   
6 
 
A17 Unknown   
7 
 
A18 Unknown   
8 
 
A18 Unknown   
9 
 
A18 Unknown   
10 
 
A19 Unknown   
11 
 
A19 Unknown   
12 
 
A19 Unknown   
13 
 
A20 Unknown   
14 
 
A20 Unknown   
15 
 
A20 Unknown   
16 
 
A21 Unknown   
17 
 
A21 Unknown   
18 
 
A21 Unknown   
19 
 
A22 Unknown   
20 
 
A22 Unknown   
21 
 
A22 Unknown   
22 
 
NTC NTC   
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No. Colour Name Type Ct Given Conc (copies/reaction) 
23 
 
NTC NTC   
24 
 
NTC NTC   
Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
B-Control Standard  50 
2 
 
B-Control Standard  50 
3 
 
B-Control Standard  50 
4 
 
B1 Unknown   
5 
 
B1 Unknown   
6 
 
B1 Unknown   
7 
 
B2 Unknown   
8 
 
B2 Unknown   
9 
 
B2 Unknown   
10 
 
B3 Unknown   
11 
 
B3 Unknown   
12 
 
B3 Unknown   
13 
 
B4 Unknown   
14 
 
B4 Unknown   
15 
 
B4 Unknown   
16 
 
NTC NTC   
17 
 
NTC NTC   
18 
 
NTC NTC   
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Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
B-Control Standard  50 
2 
 
B-Control Standard  50 
3 
 
B-Control Standard  50 
4 
 
B5 Unknown   
5 
 
B5 Unknown   
6 
 
B5 Unknown   
7 
 
B6 Unknown   
8 
 
B6 Unknown   
9 
 
B6 Unknown   
10 
 
NTC NTC   
11 
 
NTC NTC   
12 
 
NTC NTC   
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Raw Data For Cycling A.Green 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 B-Control Standard 50 
2 B-Control Standard 50 
3 B-Control Standard 50 
4 B7 Unknown 
5 B7 Unknown 
6 B7 Unknown 
7 B8 Unknown 
8 B8 Unknown 
9 B8 Unknown 
10 B9 Unknown 
11 B9 Unknown 
12 B9 Unknown 
13 NTC NTC 
14 NTC NTC 
15 NTC NTC 
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Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
B-Control Standard  50 
2 
 
B-Control Standard  50 
3 
 
B-Control Standard  50 
4 
 
B10 Unknown   
5 
 
B10 Unknown   
6 
 
B10 Unknown   
7 
 
B11 Unknown   
8 
 
B11 Unknown   
9 
 
B11 Unknown   
10 
 
B12 Unknown   
11 
 
B12 Unknown   
12 
 
B12 Unknown   
13 
 
B13 Unknown   
14 
 
B13 Unknown   
15 
 
B13 Unknown   
16 
 
NTC NTC   
17 
 
NTC NTC   
18 
 
NTC NTC   
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Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
B-Control Standard  50 
2 
 
B-Control Standard  50 
3 
 
B-Control Standard  50 
4 
 
B14 Unknown   
5 
 
B14 Unknown   
6 
 
B14 Unknown   
7 
 
B15 Unknown   
8 
 
B15 Unknown   
9 
 
B15 Unknown   
10 
 
B16 Unknown   
11 
 
B16 Unknown   
12 
 
B16 Unknown   
13 
 
B17 Unknown   
14 
 
B17 Unknown   
15 
 
B17 Unknown   
16 
 
NTC NTC   
17 
 
NTC NTC   
18 
 
NTC NTC   
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Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
B-Control Standard  50 
2 
 
B-Control Standard  50 
3 
 
B-Control Standard  50 
4 
 
B18 Unknown   
5 
 
B18 Unknown   
6 
 
B18 Unknown   
7 
 
B19 Unknown   
8 
 
B19 Unknown   
9 
 
B19 Unknown   
10 
 
B20 Unknown   
11 
 
B20 Unknown   
12 
 
B20 Unknown   
13 
 
B21 Unknown   
14 
 
B21 Unknown   
15 
 
B21 Unknown   
16 
 
B22 Unknown   
17 
 
B22 Unknown   
18 
 
B22 Unknown   
19 
 
NTC NTC   
20 
 
NTC NTC   
21 
 
NTC NTC   
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Appendix A3. Rotor-Gene Q curves for detection sensitivity of RT-LAMP RSV 
subgroups A and B. 
Raw Data For Cycling A.Green 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
RSV-A (10^4) Standard  10000 
2 
 
RSV-A (10^4) Standard  10000 
3 
 
RSV-A (10^4) Standard  10000 
4 
 
RSV-A (10^3) Standard  1000 
5 
 
RSV-A (10^3) Standard  1000 
6 
 
RSV-A (10^3) Standard  1000 
7 
 
RSV-B (10^4) Standard  10000 
8 
 
RSV-B (10^4) Standard  10000 
9 
 
RSV-B (10^4) Standard  10000 
10 
 
RSV-B (10^3) Standard  1000 
11 
 
RSV-B (10^3) Standard  1000 
12 
 
RSV-B (10^3) Standard  1000 
13 
 
NTC NTC   
14 
 
NTC NTC   
15 
 
NTC NTC   
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Raw Data For Cycling A.Green 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 RSV-A (10^2) Standard 100 
2 RSV-A (10^2) Standard 100 
3 RSV-A (10^2) Standard 100 
4 RSV-B (10^2) Standard 100 
5 RSV-B (10^2) Standard 100 
6 RSV-B (10^2) Standard 100 
7 NTC NTC 
8 NTC NTC 
9 NTC NTC 
Raw Data For Cycling A.Green 
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No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
RSV-A (10^1) Standard  10 
2 
 
RSV-A (10^1) Standard  10 
3 
 
RSV-A (10^1) Standard  10 
4 
 
RSV-B (10^1) Standard  10 
5 
 
RSV-B (10^1) Standard  10 
6 
 
RSV-B (10^1) Standard  10 
7 
 
NTC NTC   
8 
 
NTC NTC   
9 
 
NTC NTC   
 
Raw Data For Cycling A.Green (5 FFU’s Run 1) 
 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
RSV-A (10^0.5) Standard  5 
2 
 
RSV-A (10^0.5) Standard  5 
3 
 
RSV-A (10^0.5) Standard  5 
4 
 
RSV-B (10^0.5) Standard  5 
5 
 
RSV-B (10^0.5) Standard  5 
6 
 
RSV-B (10^0.5) Standard  5 
7 
 
NTC NTC   
8 
 
NTC NTC   
9 
 
NTC NTC   
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Raw Data For Cycling A.Green (5 FFU’s Run 2) 
 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 
 
RSV-A (10^5) Standard  5 
2 
 
RSV-A (10^5) Standard  5 
3 
 
RSV-A (10^0.5) Standard  5 
4 
 
RSV-B (10^5) Standard  5 
5 
 
RSV-B (10^0.5) Standard  5 
6 
 
RSV-B (10^0.5) Standard  5 
7 
 
NTC NTC   
8 
 
NTC NTC   
9 
 
NTC NTC   
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Table A3. Amplification times for RT-LAMP sensitivity testing for RSV A and B. 
Specimen Specimen
FFU/reaction FFU/reaction
A10^4 16:00 B10^4 27:30
A10^4 16:00 B10^4 25:00
A10^4 17:00 B10^4 23:00
A10^3 21:00 B10^3 33:00
A10^3 21:00 B10^3 35:00
A10^3 21:00 B10^3 35:00
A10^2 21:30 B10^2 30:00
A10^2 21:30 B10^2 34:00
A10^2 22:00 B10^2 34:00
A10^1 20:00 B10^1 36:30
A10^1 21:30 B10^1 39:00
A10^1 21:30 B10^1 39:00
A10^0.5 no amplification B10^0.5 no amplification
A10^0.5 no amplification B10^0.5 no amplification
A10^0.5 34:00 B10^0.5 38:00
A10^0.5 43:00 B10^0.5 31:00
A10^0.5 no amplification B10^0.5 no amplification
A10^0.5 no amplification B10^0.5 no amplification
Amplification Time 
(min:sec) 
Amplification Time 
(min:sec) 
Appendix A4. Rotor-Gene Q curves for reproducibility of RT-LAMP testing for RSV A 
and B. 
 Raw Data For Cycling A.Green 
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No. Colour Name Type Ct Given Conc (copies/reaction) 
1 A-Control Standard 50 
2 A-Control Standard 50 
3 A-Control Standard 50 
4 A1 Unknown 
5 A2 Unknown 
6 A3 Unknown 
7 B-Control Standard 50 
8 B-Control Standard 50 
9 B-Control Standard 50 
10 B1 Unknown 
11 B2 Unknown 
12 B3 Unknown 
13 NTC NTC 
14 NTC NTC 
15 NTC NTC 
Raw Data For Cycling A.Green 
No. Colour Name Type Ct Given Conc (copies/reaction) 
1 A-Control Standard 50 
2 A-Control Standard 50 
3 A-Control Standard 50 
4 A1 Unknown 
5 A2 Unknown 
6 A3 Unknown 
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No. Colour Name Type Ct Given Conc (copies/reaction) 
7 B-Control Standard 50 
8 B-Control Standard 50 
9 B-Control Standard 50 
10 B1 Unknown 
11 B2 Unknown 
12 B3 Unknown 
13 NTC NTC 
14 NTC NTC 
15 NTC NTC 
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